Cargando…
Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions
Cancer immunotherapy is a promising approach that has recently gained its importance in treating cancer. Despite various approaches of immunotherapies being used to target cancer cells, they are either not effective against all types of cancer or for all patients. Although efforts are being made to...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586057/ https://www.ncbi.nlm.nih.gov/pubmed/33116895 http://dx.doi.org/10.2147/CMAR.S265828 |
_version_ | 1783599919705096192 |
---|---|
author | Zeng, Guoming Jin, Libo Ying, Qinsi Chen, Haojie Thembinkosi, Murinda Charmaine Yang, Chunguang Zhao, Jinlong Ji, Hao Lin, Sue Peng, Renyi Zhang, Maolan Sun, Da |
author_facet | Zeng, Guoming Jin, Libo Ying, Qinsi Chen, Haojie Thembinkosi, Murinda Charmaine Yang, Chunguang Zhao, Jinlong Ji, Hao Lin, Sue Peng, Renyi Zhang, Maolan Sun, Da |
author_sort | Zeng, Guoming |
collection | PubMed |
description | Cancer immunotherapy is a promising approach that has recently gained its importance in treating cancer. Despite various approaches of immunotherapies being used to target cancer cells, they are either not effective against all types of cancer or for all patients. Although efforts are being made to improve the cancer immunotherapy in all possible ways, one important hindrance that lowers the immune response to kill cancer cells is the infiltration of Regulatory T (Treg) cells into the tumor cells, favoring tumor progression, on one hand, and inhibiting the activation of T cells to respond to cancer cells, on the other hand. Therefore, new anti-cancer drugs and vaccines fail to show promising results against cancer. This is due to the infiltration of Treg cells into the tumor region and suppression of anti-cancer activity. Thus, regardless of various types of immunotherapies being practiced, understanding the mechanisms of how Treg cells favor tumor progression and inhibition of anti-cancer activity is worthwhile. Therefore, the review highlights the importance of Tregs cells and how depletion of Treg cells can pave the way to an effective immunotherapy by activating the immune responses against cancer. |
format | Online Article Text |
id | pubmed-7586057 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-75860572020-10-27 Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions Zeng, Guoming Jin, Libo Ying, Qinsi Chen, Haojie Thembinkosi, Murinda Charmaine Yang, Chunguang Zhao, Jinlong Ji, Hao Lin, Sue Peng, Renyi Zhang, Maolan Sun, Da Cancer Manag Res Review Cancer immunotherapy is a promising approach that has recently gained its importance in treating cancer. Despite various approaches of immunotherapies being used to target cancer cells, they are either not effective against all types of cancer or for all patients. Although efforts are being made to improve the cancer immunotherapy in all possible ways, one important hindrance that lowers the immune response to kill cancer cells is the infiltration of Regulatory T (Treg) cells into the tumor cells, favoring tumor progression, on one hand, and inhibiting the activation of T cells to respond to cancer cells, on the other hand. Therefore, new anti-cancer drugs and vaccines fail to show promising results against cancer. This is due to the infiltration of Treg cells into the tumor region and suppression of anti-cancer activity. Thus, regardless of various types of immunotherapies being practiced, understanding the mechanisms of how Treg cells favor tumor progression and inhibition of anti-cancer activity is worthwhile. Therefore, the review highlights the importance of Tregs cells and how depletion of Treg cells can pave the way to an effective immunotherapy by activating the immune responses against cancer. Dove 2020-10-21 /pmc/articles/PMC7586057/ /pubmed/33116895 http://dx.doi.org/10.2147/CMAR.S265828 Text en © 2020 Zeng et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Zeng, Guoming Jin, Libo Ying, Qinsi Chen, Haojie Thembinkosi, Murinda Charmaine Yang, Chunguang Zhao, Jinlong Ji, Hao Lin, Sue Peng, Renyi Zhang, Maolan Sun, Da Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions |
title | Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions |
title_full | Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions |
title_fullStr | Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions |
title_full_unstemmed | Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions |
title_short | Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions |
title_sort | regulatory t cells in cancer immunotherapy: basic research outcomes and clinical directions |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586057/ https://www.ncbi.nlm.nih.gov/pubmed/33116895 http://dx.doi.org/10.2147/CMAR.S265828 |
work_keys_str_mv | AT zengguoming regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections AT jinlibo regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections AT yingqinsi regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections AT chenhaojie regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections AT thembinkosimurindacharmaine regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections AT yangchunguang regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections AT zhaojinlong regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections AT jihao regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections AT linsue regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections AT pengrenyi regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections AT zhangmaolan regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections AT sunda regulatorytcellsincancerimmunotherapybasicresearchoutcomesandclinicaldirections |